33 results about "Synaptic cleft" patented technology

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and / or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat / prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

The invention relates to a floating gate memristor. The basic structure of the floating gate memristor successively includes a front electrode, a front dielectric layer, a front floating gate layer, a nanometer battery anode, a nanometer battery electrolyte, a nanometer battery cathode, a rear floating gate layer, a rear dielectric layer and a rear electrode, wherein the front electrode, the front dielectric layer, the front floating gate layer and the nanometer battery anode simulate a presynaptic membrane which converting electronic signals to ion signals by utilizing electronic tunnel transfer and field effect; the nanometer battery electrolyte serves an ion channel simulating a synaptic cleft; the nanometer battery cathode, the rear floating gate, the rear dielectric layer and the rear electrode simulate a subsynaptic membrane which converts the ion signals to electronic signals. The floating gate memristor is stable in reading and writing, good in controllability, simple in structure, compatible to CMOS, easy to integrate, suitable for large scale production and commercialization and capable of promoting development of nervous system calculation and encephaloid calculation.

The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.

The invention discloses a novel carbon fiber nanocone electrode as well as a preparation method and application thereof, belonging to the field of electrochemistry and material science. The novel carbon fiber nanocone electrode comprises a carbon fiber, an electrode lead and a glass capillary tube, wherein the carbon fiber is connected with the electrode lead through a conductive adhesive; the front part, as long as 50-100 microns, of the carbon fiber is etched to be of a needle shape, and the tip end of the needle-shaped part has the diameter of 100nm-300nm; one end of the glass capillary tube is pulled to form a tip end with the diameter less than or equal to 1micron; the carbon fiber connected with the electrode lead penetrates into the pulled tip of the glass capillary tube, and is exposed out of the tip end of the glass capillary tube; the electrode lead is exposed out of the other end of the glass capillary tube, and the end is sealed by an AB adhesive. According to the invention, the problem that after a nano electrode is insulated, the tip end cannot be exposed easily is solved radically. The carbon fiber nanocone electrode provided by the invention has the advantages of low noise, high sensitivity and high temporal-spatial resolution, and can be applied to real-time detection on neurotransmitter in synaptic cleft in neuroscience research.

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and / or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

The invention discloses a preparation method of an electronic device with artificial synapsis at two ends based on organic / inorganic hybrid perovskite, and belongs to the field of the electronic device. The preparation method comprises the following steps: pre-treating a high-doped silicon substrate, spinning-coating a configured perovskite solution on a substrate, performing annealing treatment to obtain a perovskite thin film with good crystallinity; and then evaporating a metal top electrode to obtain the electronic device with perovskite artificial synapsis at two ends. Since the top electrode simulates the biological synapsis cephacoria, a perovskite active layer simulates the synaptic cleft, and a bottom electrode simulates synapsis caudacoria, the perovskite artificial synapsis hascomparatively high sensitivity (100mA), and the dual-pulse facilitation, the peak voltage dependence plasticity, peak persistent dependence plasticity and peak frequency dependence plasticity are realized. The preparation method disclosed by the invention not only can effectively simplify the basic structures of the perovskite artificial synapsis at two ends, the sensitivity is improved, the energy consumption is reduced, and the preparation method has significance for the development of the neuromorphic engineering and the human-like robot.

The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiestersa-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.

The invention discloses a neuron-like all-optical memory device based on Ge2Sb2Te5, and belongs to the technical field of picosecond laser application. The neuron-like all-optical memory device is based on a multi-pulse action and an STDP neural memory theory. The amorphous Ge2Sb2Te5 is coupled with optical waveguide. Ge2Sb2Te5 is attached to the optical waveguide by a way of magnetron sputtering,and a coupling region is a bionic neural synaptic cleft. The device can realize the reading, memory and erasing processes of the device through all-optical signals. Moreover, the refractive index ofcrystalline Ge2Sb2Te5 is higher than that of amorphous Ge2Sb2Te5, so the material after crystallization is easier to deflect to the direction of Ge2Sb2Te5 than that of amorphous light, the informationretention in the memory region is facilitated, and the device continuously strengthens recording in use.

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and / or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

The invention discloses application of a Xinnaoxin capsule in preparation of an antidepressant. According to experimental studies, the Xinnaoxin capsule can substantially reduce dead time during tail suspension and forced swimming of behavioral despair model mice; according to open field experiments, spontaneous activities of the mice are not influenced while dead time is substantially decreased, which prompts that the Xinnaoxin capsule has a certain anti-depression effect. Meanwhile, the Xinnaoxin capsule can substantially inhibit activity of monoamine oxidase and increase the content of a monoamine neurotransmitter in a synaptic cleft, which proves that the Xinnaoxin capsule has the anti-depression effect. Moreover, the Xinnaoxin capsule can substantially antagonize decrease of body temperature of the mice caused by reserpine and apomorphine and increase exogenous toxicity given to NE, which reveals that the capsule has the anti-depression effect. The anti-depression effect of the capsule is realized through improvement of the level of the monoamine neurotransmitter in the synaptic cleft.

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and / or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat / prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

The invention provides medicinal application of polyene phosphatidylcholine in treating cognitive functional disorder, which adopts a clinically commonly used medicine for protecting the liver - the polyene phosphatidylcholine to be a novel medicine for treating the cognitive functional disorder. As proved by clinical application and animal experiments, the polyene phosphatidylcholine has influence on improving the cognitive functional disorder and the memory function and has good effect of treating the cognitive functional disorder. Due to introduction of 'polyene' radicals which are more fat-soluble, the polyene phosphatidylcholine is more favorable to pass through blood-brain barriers and can be completely taken by neurons; and choline products produced by decomposition of the polyene phosphatidylcholine by the neurons can be further synthesized into acetylcholine in the neurons, thereby compensating for choline exhausted by synaptic clefts. The polyene phosphatidylcholine can generate the choline, DHA and an arachidonic acid during the process of metabolism, is a medicine for treating the cognitive functional disorder which has moderate price and small toxic and side effect, and is safe and reliable, and can also become a medicine for improving intelligence.

The invention provides medicinal application of polyene phosphatidylcholine in treating cognitive functional disorder, which adopts a clinically commonly used medicine for protecting the liver - the polyene phosphatidylcholine to be a novel medicine for treating the cognitive functional disorder. As proved by clinical application and animal experiments, the polyene phosphatidylcholine has influence on improving the cognitive functional disorder and the memory function and has good effect of treating the cognitive functional disorder. Due to introduction of 'polyene' radicals which are more fat-soluble, the polyene phosphatidylcholine is more favorable to pass through blood-brain barriers and can be completely taken by neurons; and choline products produced by decomposition of the polyene phosphatidylcholine by the neurons can be further synthesized into acetylcholine in the neurons, thereby compensating for choline exhausted by synaptic clefts. The polyene phosphatidylcholine can generate the choline, DHA and an arachidonic acid during the process of metabolism, is a medicine for treating the cognitive functional disorder which has moderate price and small toxic and side effect, and is safe and reliable, and can also become a medicine for improving intelligence.

The present invention provides a therapy for treating neuropathic pain by subpial administration of small quantities of a composition for spinal segment-specific upregulation of GAD65 (glutamatedecarboxylase) gene and VGAT (vesicular GABA transporter) gene, which is effective for induction of nociceptive effects by potentiating release of vesicular GABA from infected dorsal horn neurons into the synaptic cleft.

The invention provides a kind of medicine with neuroprotective effect and application thereof. The medicine is theaflavin-3'-gallate, and its structure is shown in formula (I). Described compound of formula (I) has obvious effect in terms of depressive neurosis, and the antidepressant effect of theaflavin-3'-gallate is mainly by increasing the content of 5-HT and DA in the brain, improving the synaptic cleft nerve. The concentration of the transmitter can be achieved, which can obviously relieve and treat nervous symptoms. The theaflavin-3'-gallate of the present invention also has a good curative effect in the aspect of cardiac neurosis.

The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition, and a use thereof. The compound is used for treating, preventing and / or controlling various nervous system disorders. The compound provided herein modulates one or more monoaminetransporters, inhibits reuptake of endogenous monoamines such as dopamine, serotonin, and norepinephrine (e.g., from synaptic clearances), and / or modulates the 5-HT3 receptor.

The invention discloses an ionic two-end bionic memristor and a preparation method thereof. The ionic two-end bionic memristor device comprises a substrate, bottom electrodes which are formed on the substrate, are arranged in parallel along a first direction at certain intervals and serve as one end of the memristor, ionic gel which is formed on the bottom layer electrode and serves as a functional layer of the memristor, and top electrodes which are formed on the ionic gel, are arranged in parallel along a second direction at certain intervals, are in a cross array structure with the bottom electrodes, and serve as the other end of the memristor, wherein two ends of the memristor respectively correspond to a synaptic front end and a synaptic rear end, a functional layer of the memristor corresponds to a synaptic gap, ion migration in brain-like nerve synapses is simulated by utilizing diffusibility of ions in the ionic gel, information transmission of a conductive channel is realized, an ion channel effect in a similar organism is simulated, and a nerve synapse weight modulation process is completed.

The invention discloses a neuron-like all-optical memory device based on Ge2Sb2Te5, and belongs to the technical field of picosecond laser application. The neuron-like all-optical memory device is based on a multi-pulse action and an STDP neural memory theory. The amorphous Ge2Sb2Te5 is coupled with optical waveguide. Ge2Sb2Te5 is attached to the optical waveguide by a way of magnetron sputtering,and a coupling region is a bionic neural synaptic cleft. The device can realize the reading, memory and erasing processes of the device through all-optical signals. Moreover, the refractive index ofcrystalline Ge2Sb2Te5 is higher than that of amorphous Ge2Sb2Te5, so the material after crystallization is easier to deflect to the direction of Ge2Sb2Te5 than that of amorphous light, the informationretention in the memory region is facilitated, and the device continuously strengthens recording in use.

The invention is directed to dual-analyte fluorescent chemosensors for the direct detection and visualization (imaging) of neurotransmitters released upon exocytosis. The inventive sensor exploits the high concentration of neurotransmitters (e.g., glutamate, norepinephrine, and dopamine) and capitalizes upon the pH gradient between the vesicle and synaptic cleft.

The invention is directed to dual-analyte fluorescent chemosensors for the direct detection and visualization (imaging) of neurotransmitters released upon exocytosis. The inventive sensor exploits the high concentration of neurotransmitters (e.g., glutamate, norepinephrine, and dopamine) and capitalizes upon the pH gradient between the vesicle and synaptic cleft.

The invention discloses a preparation method of an electronic device with artificial synapsis at two ends based on organic / inorganic hybrid perovskite, and belongs to the field of the electronic device. The preparation method comprises the following steps: pre-treating a high-doped silicon substrate, spinning-coating a configured perovskite solution on a substrate, performing annealing treatment to obtain a perovskite thin film with good crystallinity; and then evaporating a metal top electrode to obtain the electronic device with perovskite artificial synapsis at two ends. Since the top electrode simulates the biological synapsis cephacoria, a perovskite active layer simulates the synaptic cleft, and a bottom electrode simulates synapsis caudacoria, the perovskite artificial synapsis hascomparatively high sensitivity (100mA), and the dual-pulse facilitation, the peak voltage dependence plasticity, peak persistent dependence plasticity and peak frequency dependence plasticity are realized. The preparation method disclosed by the invention not only can effectively simplify the basic structures of the perovskite artificial synapsis at two ends, the sensitivity is improved, the energy consumption is reduced, and the preparation method has significance for the development of the neuromorphic engineering and the human-like robot.

The invention provides a drug with a neuroprotective effect and application of the drug. The drug is theaflavin-3'-gallate, and a structure of the drug is shown as a formula (I). A compound of the formula (I) has obvious effects on depressive neurosis, the antidepressant effect of theaflavin-3'-gallate is mainly realized by increasing the content of 5-HT and DA in brain and increasing the concentration of synaptic cleft neurotransmitter, and theaflavin-3'-gallate has obvious relieving and therapeutic effects on nervous tension symptoms. The theaflavin-3'-gallate further has a good curative effect on cardiac neurosis.

The invention discloses application of a Xinnaoxin capsule in preparation of an antidepressant. According to experimental studies, the Xinnaoxin capsule can substantially reduce dead time during tail suspension and forced swimming of behavioral despair model mice; according to open field experiments, spontaneous activities of the mice are not influenced while dead time is substantially decreased, which prompts that the Xinnaoxin capsule has a certain anti-depression effect. Meanwhile, the Xinnaoxin capsule can substantially inhibit activity of monoamine oxidase and increase the content of a monoamine neurotransmitter in a synaptic cleft, which proves that the Xinnaoxin capsule has the anti-depression effect. Moreover, the Xinnaoxin capsule can substantially antagonize decrease of body temperature of the mice caused by reserpine and apomorphine and increase exogenous toxicity given to NE, which reveals that the capsule has the anti-depression effect. The anti-depression effect of the capsule is realized through improvement of the level of the monoamine neurotransmitter in the synaptic cleft.